When compared with people taking metformin, those prescribed GLP-1 receptor agonists experienced: a 26% lower risk of death from any cause , a 13% reduction in hospitalizations , up to a 48% lower risk of amputation , approximately a 36% reduction in procedures to reopen blocked leg arteries
Two earlier studies (NCT01689233 and NCT01689246) conducted on participants with mild AD and mild to moderate AD, respectively, indicated that the drug demonstrated good safety and potential benefits as a monotherapy
When hes not fasting, Attia takes 400-500mg of magnesium oxide
Other secondary or exploratory outcomes include an expanded composite endpoint, which adds death from any cause or coronary revascularization to the 3-point MACE
However, because of the discovery of insulin, metformin research was put on hold